Multi-scale transcriptomics analysis reveals MHC suppression in MEF2D fusion positive B-cell acute lymphoblastic...

Area of Science:

• Hematology
• Molecular Biology
• Immunology

Background:

• MEF2D gene fusions characterize a distinct B-cell precursor acute lymphoblastic leukemia (BCP-ALL) subtype with a poor prognosis.
• Understanding the molecular mechanisms driving this subtype is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the molecular features and pathogenic mechanisms of MEF2D-fusion BCP-ALL.
• To identify potential therapeutic targets by analyzing gene expression and protein interactions.

Main Methods:

• Single-cell RNA sequencing (scRNA-seq) on MEF2D fusion BCP-ALL cases and public datasets.
• Comparison with normal bone marrow cells and other BCP-ALL subtypes.
• Cell-cell communication analysis, bulk RNA-seq, gene knockdown experiments, and ChIP-seq.

Main Results:

• Identified a specific pre-B cell developmental arrest in MEF2D-fusion BCP-ALL.
• Observed significant downregulation of Major Histocompatibility Complex (MHC) expression, suggesting immune evasion.
• Confirmed CIITA (MHC transactivator) downregulation and demonstrated that MEF2D-HNRNPUL1 fusion protein directly binds to CIITA regulatory regions, impacting MHC expression.

Conclusions:

• MEF2D fusions induce a unique BCP-ALL subtype characterized by developmental arrest and immune evasion.
• A novel pathogenic mechanism involving MEF2D-CIITA-MHC pathway is proposed.
• Findings provide insights into the biology of MEF2D-fusion BCP-ALL and suggest potential therapeutic strategies targeting this pathway.